LinkedIn Content Strategy & Writing Style
Founder & CEO @ Flot.bio
1 person tracking this creator on Viral Brain
Philip Hemme positions himself as the premier biotech ecosystem cartographer, bridging the gap between high-level pharmaceutical investment and technical scientific innovation. His content strategy centers on high-utility data visualizations, such as his viral biotech maps, paired with long-form executive interviews that humanize the "shadow powerhouses" of the industry. He is notable for his ability to translate complex clinical milestones and $12B mergers into accessible market intelligence, moving beyond mere news reporting to provide a structured view of private biotech landscapes. By intersecting media-driven transparency with proprietary data tools, Hemme has built a unique value proposition where his platform serves as both a discovery engine for investors and a high-signal stage for the sector’s most influential founders.
31.9K
28.6K
329
—
1.1
111
5
Remarkable private biotechs ahead! As always, you can access the data behind the map for free in our app, below: 👉 https://map.flot.bio/ Criteria: Therapeutics only. Prioritized significant fundrai…
Here’s what really mattered in 2025, to me 🤓 1. Abivax 🇫🇷 hits a Phase 3 home-run in inflammatory bowel disease, sending its stock through the roof (+1700% YTD). The biggest jump of any European s…
RECORDING: Fredrik Tiberg has built one of the best biotechs you may have never heard of: Camurus 🇸🇪 At least that’s what I realized when preparing for the interview. We talked about the journey…
Here’re the most important news from the biggest biotech conference of the year, from Union Square in the heart of San Francisco: Nothing 🙃 Literally zero major news drops (no upfront or M&A >$100M…
EPISODE: Pascal has brought two first-in-class cell therapies to patients. Now, he’s helping and investing in others to do the same. He also relates how European biotechs and investors missed out on…
EPISODE: Beginning of 2025, Sten announced Cereno Scientific’s positive Phase 2a results. He’s now moving forward with a global Ph2b trial. “We’ve got this data [in PAH], we’ve got the fast-track, th…
1.1 posts/week
Posts / Week
7.2 days
Days Between Posts
5
Total Posts Analyzed
MEDIUM
Posting Frequency
328.5%
Avg Engagement Rate
STABLE
Performance Trend
210
Avg Length (Words)
HIGH
Depth Level
ADVANCED
Expertise Level
0.82/10
Uniqueness Score
YES
Question Usage
0.18%
Response Rate
Writing style breakdown
<start of post>
EPISODE: In 2018, the team at BioVersa was just three people in a shared lab. Today, they’ve raised $150M and are entering Phase 2 with a first-in-class oncology asset.
We spent three years just perfecting the delivery mechanism. Everyone told us it was impossible, but we knew the data was there.
BioVersa is developing a new class of RNA therapeutics that target hard-to-reach solid tumors. It’s a high-stakes bet in a crowded field.
The goal isn't just to extend life by months, but to fundamentally change the treatment paradigm for these patients.
We talked about the challenges of raising a Series B in a down market, the importance of clinical site selection in Eastern Europe, and why the CEO still spends Friday afternoons in the lab.
You have to stay close to the science. If you lose that childish curiosity, you lose the soul of the company.
This is one of the most transparent conversations I’ve had about the 'valley of death' in biotech.
You can now watch and listen to the full episode for free on YouTube, Spotify or Apple (link in the comments 👇)
-----
Learn how YSDS helps move your most sensitive life sciences shipments worldwide, safely, on time, with full visibility at https://bit.ly/ysds-bio
-----
P.S. We recorded this in their new London office. The view of the Shard is incredible! 🏙️
<end of post>
Sign in to unlock the full writing analysis
Nail your LinkedIn strategy with ViralBrain.
Analyze and write in Philip Hemme's style. Grow your LinkedIn to the next level.